{"raw_mentions": "As used herein, \u201cspecific binding\u201d or \u201cimmunospecific binding\u201d or \u201cbinds immunospecifically\u201d refer to antibody binding to a predetermined antigen (e.g. IGF-1R) or epitope present on the antigen. \nIn some embodiments, the antibody binds with a dissociation constant (K<sub>D</sub>) of 10<sup>\u22127 </sup>M or less, and binds to the predetermined antigen with a K<sub>D </sub>that is at least two-fold less than its K<sub>D </sub>for binding to a non-specific antigen (e.g., BSA, casein, or another non-specific polypeptide) other than the predetermined antigen."}
{"final_json": [{"molecule_name": null, "protein_target_name": "IGF-1R", "binding_metric": "Kd", "value": "<10\u22127", "unit": "M", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": "BSA", "binding_metric": "Kd", "value": null, "unit": null, "is_logarithmic": false}]}
{"raw_mentions": "In some embodiments, the antibody has an IC50 of less than, or equal to, about 0.2 nm, 0.15 nm, 0.10 nm, 0.09 nm.\nIn some embodiments, the antibody has a serum concentration in the subject of at least, or about, 70 \u03bcg/ml, 75 \u03bcg/ml, 80 \u03bcg/ml, 85 \u03bcg/ml, 90 \u03bcg/ml, 95 \u03bcg/ml, 100 \u03bcg/ml, or 105 \u03bcg/ml at least 1, 2, or 3 weeks after administration."}
{"final_json": [{"molecule_name": "antibody", "protein_target_name": null, "binding_metric": "IC50", "value": "<= 0.2", "unit": "nm", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": "IC50", "value": "<= 0.15", "unit": "nm", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": "IC50", "value": "<= 0.10", "unit": "nm", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": "IC50", "value": "<= 0.09", "unit": "nm", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": null, "value": ">= 70", "unit": "\u03bcg/ml", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": null, "value": ">= 75", "unit": "\u03bcg/ml", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": null, "value": ">= 80", "unit": "\u03bcg/ml", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": null, "value": ">= 85", "unit": "\u03bcg/ml", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": null, "value": ">= 90", "unit": "\u03bcg/ml", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": null, "value": ">= 95", "unit": "\u03bcg/ml", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": null, "value": ">= 100", "unit": "\u03bcg/ml", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": null, "value": ">= 105", "unit": "\u03bcg/ml", "is_logarithmic": false}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n91. The method of any one of embodiments 88-90, wherein the antibody has an IC50 of less than, or equal to, about 0.2 nm, 0.15 nm, 0.10 nm, 0.09 nm.\n94. A method of treating thyroid eye disease in a subject, the method comprising administering an antibody of any one of embodiments 1-44 or as otherwise provided for herein, or a pharmaceutical composition comprising the same to the subject, wherein the antibody has a serum concentration in the subject of at least, or about, 70 \u03bcg/ml, 75 \u03bcg/ml, 80 \u03bcg/ml, 85 \u03bcg/ml, 90 \u03bcg/ml, 95 \u03bcg/ml, 100 \u03bcg/ml, or 105 \u03bcg/ml at least 1, 2, or 3 week after administration."}
{"final_json": [{"molecule_name": "antibody", "protein_target_name": null, "binding_metric": "IC50", "value": "<=0.2", "unit": "nm", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": "IC50", "value": "<=0.15", "unit": "nm", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": "IC50", "value": "<=0.10", "unit": "nm", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": "IC50", "value": "<=0.09", "unit": "nm", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": null, "value": ">=70", "unit": "\u03bcg/ml", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": null, "value": ">=75", "unit": "\u03bcg/ml", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": null, "value": ">=80", "unit": "\u03bcg/ml", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": null, "value": ">=85", "unit": "\u03bcg/ml", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": null, "value": ">=90", "unit": "\u03bcg/ml", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": null, "value": ">=95", "unit": "\u03bcg/ml", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": null, "value": ">=100", "unit": "\u03bcg/ml", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": null, "value": ">=105", "unit": "\u03bcg/ml", "is_logarithmic": false}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n155. The method of embodiments 153 or 154, wherein the antibody has an IC50 of less than, or equal to, about 0.2 nm, 0.15 nm, 0.10 nm, 0.09 nm.\n158. A method of treating thyroid eye disease in a subject, the method comprising administering an antibody of any one of embodiments 107-111, or a pharmaceutical composition comprising the same to the subject, wherein the antibody has a serum concentration in the subject of at least, or about, 70 \u03bcg/ml, 75 \u03bcg/ml, 80 \u03bcg/ml, 85 \u03bcg/ml, 90 \u03bcg/ml, 95 \u03bcg/ml, 100 \u03bcg/ml, or 105 \u03bcg/ml at least 1, 2, or 3 weeks after administration."}
{"final_json": [{"molecule_name": null, "protein_target_name": null, "binding_metric": "IC50", "value": "<=0.2", "unit": "nm", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "IC50", "value": "<=0.15", "unit": "nm", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "IC50", "value": "<=0.10", "unit": "nm", "is_logarithmic": false}, {"molecule_name": null, "protein_target_name": null, "binding_metric": "IC50", "value": "<=0.09", "unit": "nm", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": null, "value": ">=70", "unit": "\u03bcg/ml", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": null, "value": ">=75", "unit": "\u03bcg/ml", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": null, "value": ">=80", "unit": "\u03bcg/ml", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": null, "value": ">=85", "unit": "\u03bcg/ml", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": null, "value": ">=90", "unit": "\u03bcg/ml", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": null, "value": ">=95", "unit": "\u03bcg/ml", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": null, "value": ">=100", "unit": "\u03bcg/ml", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": null, "value": ">=105", "unit": "\u03bcg/ml", "is_logarithmic": false}]}
{"raw_mentions": "208. The method of any one of embodiments 205-207, wherein the antibody has an IC50 of less than, or equal to, about 0.2 nm, 0.15 nm, 0.10 nm, 0.09 nm."}
{"final_json": [{"molecule_name": "antibody", "protein_target_name": null, "binding_metric": "IC50", "value": "<=0.2 nm, 0.15 nm, 0.10 nm, 0.09 nm", "unit": "nm", "is_logarithmic": false}]}
{"raw_mentions": "254. The method of any one of embodiments 251-253, wherein the antibody has an IC50 of less than, or equal to, about 0.2 nm, 0.15 nm, 0.10 nm, 0.09 nm."}
{"final_json": [{"molecule_name": "antibody", "protein_target_name": null, "binding_metric": "IC50", "value": "<=0.2 nm", "unit": "nm", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": "IC50", "value": "<=0.15 nm", "unit": "nm", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": "IC50", "value": "<=0.10 nm", "unit": "nm", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": null, "binding_metric": "IC50", "value": "<=0.09 nm", "unit": "nm", "is_logarithmic": false}]}
{"raw_mentions": "VRDN-1100 is a humanized monoclonal antibody targeting IGF-1R with an equilibrium dissociation constant KD of 1.8 nM.\nNo other relevant sentences were found in the provided text snippet."}
{"final_json": [{"molecule_name": "VRDN-1100", "protein_target_name": "IGF-1R", "binding_metric": "KD", "value": "1.8", "unit": "nM", "is_logarithmic": false}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nAs illustrated in FIG. 3D, in, the binding dose response curve demonstrated VRDN-1100 EC50=0.1 nM.\nThe lower panel of FIG. 5B illustrates a binding dose response curve, which demonstrated VRDN-1100 having an EC50=0.4 nM.\nVRDN-1100 potently inhibits IGF-1 stimulated receptor phosphorylation on A549 cells (IC50=0.09 nM) and HOCF cells (IC50=0.09 nM), which is illustrated in FIG. 6A and FIG. 6B."}
{"final_json": [{"molecule_name": "VRDN-1100", "protein_target_name": null, "binding_metric": "EC50", "value": "0.1", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "VRDN-1100", "protein_target_name": null, "binding_metric": "EC50", "value": "0.4", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "VRDN-1100", "protein_target_name": "IGF-1", "binding_metric": "IC50", "value": "0.09", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "VRDN-1100", "protein_target_name": "IGF-1", "binding_metric": "IC50", "value": "0.09", "unit": "nM", "is_logarithmic": false}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nThe YTE Fc mutatant version of VRDN1100 was found to bind to A549 cells with an EC50 of 0.30 nm and the C22S and Fc YTE mutant had an EC50 of 0.36 nm.\nThe YTE only mutant had an IC50 of 0.40 nm and the C22S plus YTE mutations had an IC50 of 0.37 nm.\nUsing this assay, the antibody was found to bind to IGF-1R with a k<sub>a </sub>(1/Ms) of 1.04\u00d710<sup>5</sup>, a k<sub>d </sub>(1/s) of 2.18\u00d710<sup>\u22125</sup>, and a K<sub>D</sub>(M) of 2.10\u00d710<sup>\u221210 </sup>at a pH of 7.4."}
{"final_json": [{"molecule_name": "VRDN1100", "protein_target_name": "A549 cells", "binding_metric": "EC50", "value": "0.30", "unit": "nm", "is_logarithmic": false}, {"molecule_name": "C22S and Fc YTE mutant", "protein_target_name": "A549 cells", "binding_metric": "EC50", "value": "0.36", "unit": "nm", "is_logarithmic": false}, {"molecule_name": "YTE only mutant", "protein_target_name": null, "binding_metric": "IC50", "value": "0.40", "unit": "nm", "is_logarithmic": false}, {"molecule_name": "C22S plus YTE mutations", "protein_target_name": null, "binding_metric": "IC50", "value": "0.37", "unit": "nm", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": "IGF-1R", "binding_metric": "k_a", "value": "1.04\u00d710^5", "unit": "1/Ms", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": "IGF-1R", "binding_metric": "k_d", "value": "2.18\u00d710^\u22125", "unit": "1/s", "is_logarithmic": false}, {"molecule_name": "antibody", "protein_target_name": "IGF-1R", "binding_metric": "K_D", "value": "2.10\u00d710^\u221210", "unit": "M", "is_logarithmic": false}]}
